UCB Data Highlights Unmet Needs in Epilepsy Care, Bolsters FINTEPLA Value Proposition
Event summary
- UCB presented data at the AAN 2026 meeting demonstrating significant quality-of-life impacts on epilepsy patients and caregivers, particularly those with developmental and epileptic encephalopathies (DEEs).
- A caregiver survey revealed that 27% of DEE patients experience daily sleep disturbances, negatively impacting daily living and communication.
- Real-world data showed 88% of epilepsy patients and 96% of caregivers reported seizures impacted their ability to perform normal daily activities.
- Analysis of U.S. patients using FINTEPLA (fenfluramine) for Lennox-Gastaut syndrome (LGS) showed reductions in healthcare resource utilization and antiseizure medication claims with treatment persistence.
The big picture
UCB's data underscores the significant unmet needs within the epilepsy treatment landscape, particularly for patients with rare and severe forms like DEEs and LGS. The findings highlight the broader impact of epilepsy beyond seizure control, affecting caregivers and overall quality of life. The positive data on FINTEPLA's impact on healthcare resource utilization reinforces its value proposition and strengthens UCB's position in the neurology market, which is estimated to be worth over $30 billion annually.
What we're watching
- Clinical Trials
- The focus on sleep as an endpoint in future epilepsy research suggests UCB may expand clinical trials to incorporate sleep-related metrics, potentially impacting trial design and timelines.
- Market Adoption
- The 61% persistence rate for FINTEPLA at 12 months, despite a greater disease severity in treated patients, will be a key indicator of long-term market adoption and UCB's ability to retain patients.
- Competitive Landscape
- The data highlighting the burden on caregivers and the need for improved seizure control will likely intensify competition in the epilepsy treatment space, prompting other companies to seek differentiated therapies.